With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
India Today on MSN2d
Benefits outweigh risks: Novo Nordisk India's MD on Ozempic side effectsVikrant Shrotriya, Novo Nordisk India's Managing Director, addressed concerns over the side effects of Ozempic during a ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...
You know Ozempic can help with weight loss, but how long can you stay on Ozempic exactly? Unfortunately, there isn’t a solid ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
24/7 Wall St. on MSN13d
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback